GSK-3 as potential target for therapeutic irvention in cancer

none18siThe serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer's disease, Parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.noneJ.A. McCubrey; L.S. Steelman; F.E. Bertrand; N.M. Davis; M. Sokolosky; S.L. Abrams; G. Montalto; A.B. D’Assoro; M. Libra; F. Nicoletti; R. Maestro; J. Basecke; D. Rakus; A Gizak; Z. Demidenko; L. Cocco; A.M. Martelli; M. Cervello.J.A. McCubrey; L.S. Steelman; F.E. Bertrand; N.M. Davis; M. Sokolosky; S.L. Abrams; G. Montalto; A.B. D’Assoro; M. Libra; F. Nicoletti; R. Maestro; J. Basecke; D. Rakus; A Gizak; Z. Demidenko; L. Cocco; A.M. Martelli; M. Cervello